Uliginosin B, a phloroglucinol derivative from Hypericum polyanthemum: a promising new molecular pattern for the development of antidepressant drugs

Behav Brain Res. 2012 Mar 1;228(1):66-73. doi: 10.1016/j.bbr.2011.11.031. Epub 2011 Dec 2.

Abstract

In this study we have demonstrated that cyclohexane extract of Hypericum polyanthemum (POL) and its main phloroglucinol derivative uliginosin B (ULI) present antidepressant-like activity in rodent forced swimming test (FST). The involvement of monoaminergic neurotransmission on the antidepressant-like activity of ULI was evaluated in vivo and in vitro. POL 90 mg/kg (p.o.) and ULI 10 mg/kg (p.o.) reduced the immobility time in the mice FST without altering locomotion activity in the open-field test. The combination of sub-effective doses of POL (45 mg/kg, p.o.) and ULI (5 mg/kg, p.o.) with sub-effective doses of imipramine (10 mg/kg, p.o.), bupropion (3 mg/kg, p.o.) and fluoxetine (15 mg/kg, p.o.) induced a significant reduction on immobility time in FST. The pretreatment with SCH 23390 (15 μg/kg, s.c., dopamine D1 receptor antagonist), sulpiride (50 mg/kg, i.p., dopamine D2 receptor antagonist), prazosin (1mg/kg, i.p., α1-adrenoceptor antagonist), yohimbine (1mg/kg, i.p., α2-adrenoceptor antagonist) and pCPA (100 mg/kg/day, i.p., p-chlorophenilalanine methyl ester, inhibitor of serotonin synthesis, for four consecutive days) before ULI administration (10 mg/kg, p.o.) significantly prevented the anti-immobility effect in FST. ULI was able to inhibit synaptosomal uptake of dopamine (IC50 = 90 ± 38 nM), serotonin (IC50 = 252 ± 13 nM) and noradrenaline (280 ± 48 nM), but it did not bind to any of the monoamine transporters. These data firstly demonstrated the antidepressant-like effect of POL and ULI, which depends on the activation of the monoaminergic neurotransmission in a different manner from the most antidepressants.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antidepressive Agents / isolation & purification
  • Antidepressive Agents / pharmacology*
  • Benzazepines / pharmacology
  • Biogenic Monoamines / metabolism
  • Bupropion / pharmacology
  • Drug Evaluation, Preclinical / methods
  • Drug Evaluation, Preclinical / psychology
  • Enzyme Inhibitors / pharmacology
  • Fenclonine / pharmacology
  • Fluoxetine / pharmacology
  • Hypericum / chemistry*
  • Imipramine / pharmacology
  • Immobility Response, Tonic / drug effects
  • Locomotion / drug effects
  • Male
  • Mice
  • Mice, Inbred Strains
  • Phloroglucinol / analogs & derivatives*
  • Phloroglucinol / antagonists & inhibitors
  • Phloroglucinol / isolation & purification
  • Phloroglucinol / pharmacology
  • Plant Extracts / chemistry
  • Plant Extracts / pharmacology
  • Prazosin / pharmacology
  • Rats
  • Rats, Wistar
  • Receptors, Catecholamine / antagonists & inhibitors
  • Sulpiride
  • Vesicular Monoamine Transport Proteins / metabolism
  • Yohimbine / pharmacology

Substances

  • Antidepressive Agents
  • Benzazepines
  • Biogenic Monoamines
  • Enzyme Inhibitors
  • Plant Extracts
  • Receptors, Catecholamine
  • SCH 23390
  • Vesicular Monoamine Transport Proteins
  • Fluoxetine
  • Bupropion
  • Yohimbine
  • Sulpiride
  • Phloroglucinol
  • Imipramine
  • uliginosin B
  • Fenclonine
  • Prazosin